Corporate | 8 July 2014 07:27
DGAP-News: Evotec AG / Key word(s): Alliance
08.07.2014 / 07:27
---------------------------------------------------------------------
Hamburg, Germany - 08 July 2014: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) announced today an exclusive strategic
collaboration with the Fraunhofer Institute for Molecular Biology and
Applied Ecology IME in several disease areas through the combination of the
relevant platforms of both organisations for internal and external drug
discovery projects.
This alliance expands Evotec's already powerful drug discovery platform
with access to a broad range of complementary and highly innovative
platforms and capabilities to progress own innovate projects and provides
additional capabilities for customers and partners of Evotec and IME,
respectively. The deal follows the joint decision of Evotec,
Fraunhofer-Gesellschaft and the City of Hamburg to integrate the European
ScreeningPort GmbH into the IME thereby forming the first Fraunhofer life
science institution in the City of Hamburg.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are
looking forward to partner with Fraunhofer IME and are excited about the
potential of this alliance. The IME has an impressive track record for
product development and provides an ideal basis for collaborating with one
of the strongest science organisations in Germany and beyond. This adds
another footprint in Europe of our EVT Innovate programmes as we have with
US based academic institutions."
Prof. Dr Rainer Fischer, Senior Executive Director at the Fraunhofer IME
stated: "This collaboration constitutes a win-win situation through the
project-specific combination of first-in-class capabilities. In particular,
Evotec's medicinal chemistry and expertise will add value to our own, our
joint and our partner's programmes. We look forward to collaborate with an
experienced player in the life science industry on several layers now and
in the future."
ABOUT FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME
The Fraunhofer Institute for Molecular Biology and Applied Ecology IME
conducts research in the field of applied life sciences from a molecular
level to entire ecosystems. Our interdisciplinary organization features
laboratories with the state of the art infrastructure, including GMP
production facilities and complex facilities for environmental simulations,
allowing a wide spectrum of research and development services in the
divisions of Molecular Biology and Applied Ecology.
The Molecular Biology Division focuses on complex research and projects in
the business fields Drugs and Biopharmaceuticals, Bioproduction and
Industrial Biotechnology and Agroscience for Food and Feed. The formation
of the IME-SP is fully aligned with the Fraunhofer IME mission to take
innovative products closer towards the market, to develop enabling
technologies and provide scientific services to partners from academic
institutions and industry.
The Fraunhofer IME has approximately 600 employees working at its
laboratories in Aachen, Schmallenberg, Münster, Gießen and Frankfurt as
well as subsidiary research centers in the USA and in Chile. The IME enjoys
close ties with the Institute of Molecular Biotechnology at RWTH Aachen
University, the Department of Biotechnology of Plants at the University
Münster, the Department of Applied Entomology at the University Gießen and
the Institute for Clinical Pharmacology at the Goethe University Frankfurt.
ABOUT EUROPEAN SCREENINGPORT GMBH
European ScreeningPort is located in Hamburg and was founded in 2008 as a
public private partnership. Founding shareholders include the Free and
Hanseatic City of Hamburg and Evotec AG.
The mission of the European ScreeningPort ("ESP") was to bridge the gap
between basic academic research and the life sciences industry in the field
of drug discovery and development. With state-of-the-art infrastructure at
the VolksparkLabs in Hamburg, established processes and innovative
technologies, ESP was able to position itself as a world-leading contract
research organization for small-molecule screening, particularly for
targets identified by academic partners. ESP was successful in the
competitive acquisition of public joint research projects (BMBF, EU, IMI)
and has already acquired full project capacity for several years to come.
Focusing on applied research, ESP has developed a strong network of
academic as well as pharmaceutical industry partners.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Hyperion Therapeutics in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
End of Corporate News
---------------------------------------------------------------------
08.07.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
277032 08.07.2014